Drug Trial Radar · NCT07764978
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
Last checked: Nov 19, 2026Latest source record: Aug 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
750
Planned (sponsor's estimate)
Start
Jun 26, 2026
Primary completion
Jan 11, 2029
Study completion May 12, 2034
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Aug 14, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a randomised, multicentre, controlled, open-label, Phase III global study comparing the efficacy and safety of standard induction regimens (IsaVRd and DRd) followed by AZD0120 versus standard induction regimens followed by continuous therapy (IsaRd and DRd) in participants with newly diagnosed multiple myeloma (NDMM) who are ineligible for autologous stem cell transplant (ASCT) as initial therapy.
Conditions
- Newly Diagnosed Multiple Myeloma
Interventions
AZD0120Biological
AZD0120, is a BCMA/CD19 dual CAR T-cell product, which is administered intravenously.
DaratumumabBiological
Induction, optional bridging and continuous therapy.
DexamethasoneDrug
Induction, optional bridging and continuous therapy.
IsatuximabBiological
Induction, optional bridging and continuous therapy.
LenalidomideDrug
Induction, optional bridging and continuous therapy.
BortezomibDrug
Induction therapy.
CyclophosphamideDrug
Lymphodepletion
FludarabineDrug
Lymphodepletion
Primary outcomes
What the sponsor says the trial is designed to measure.
- PFS in NDMM who are ineligible to receive ASCT is measured to demonstrate the superiority of IsaVRd or DRd induction followed by AZD0120 compared to IsaVRd or DRd induction followed by continuous DRd or IsaRd.Time frame: Up to 9 years.
- MRD negative CR rate at 9M in NDMM who are ineligible to receive ASCT is measured to demonstrate the superiority of IsaVRd or DRd induction followed by AZD0120 compared to IsaVRd or DRd induction followed by continuous DRd or IsaRdTime frame: Up to 9 years.
Locations
124 sites in 15 countries. Site status is shown where the registry gives one.
Research Site
Gilbert, Arizona · Not yet recruiting
Research Site
Phoenix, Arizona · Not yet recruiting
Research Site
Tucson, Arizona · Not yet recruiting
Research Site
Orange, California · Not yet recruiting
Research Site
Santa Monica, California · Not yet recruiting
Research Site
Aurora, Colorado · Not yet recruiting
Research Site
Denver, Colorado · Not yet recruiting
Research Site
New Haven, Connecticut · Not yet recruiting
Research Site
Coral Gables, Florida · Not yet recruiting
Research Site
Tampa, Florida · Not yet recruiting
Research Site
Atlanta, Georgia · Not yet recruiting
Research Site
Chicago, Illinois · Not yet recruiting
Research Site
Iowa City, Iowa · Not yet recruiting
Research Site
Wichita, Kansas · Not yet recruiting
Research Site
Louisville, Kentucky · Not yet recruiting
Research Site
Baton Rouge, Louisiana · Not yet recruiting
Research Site
Baltimore, Maryland · Not yet recruiting
Research Site
Detroit, Michigan · Not yet recruiting
Research Site
St Louis, Missouri · Not yet recruiting
Research Site
East Brunswick, New Jersey · Not yet recruiting
Research Site
Albany, New York · Not yet recruiting
Research Site
New Hyde Park, New York · Not yet recruiting
Research Site
New York, New York · Not yet recruiting
Research Site
New York, New York · Not yet recruiting
Research Site
New York, New York · Not yet recruiting
Research Site
The Bronx, New York · Not yet recruiting
Research Site
Chapel Hill, North Carolina · Not yet recruiting
Research Site
Charlotte, North Carolina · Not yet recruiting
Research Site
Durham, North Carolina · Not yet recruiting
Research Site
Winston-Salem, North Carolina · Not yet recruiting
Research Site
Winston-Salem, North Carolina · Not yet recruiting
Research Site
Cincinnati, Ohio · Not yet recruiting
Research Site
Cleveland, Ohio · Not yet recruiting
Research Site
Columbus, Ohio · Not yet recruiting
Research Site
Montgomery, Ohio · Not yet recruiting
Research Site
Portland, Oregon · Not yet recruiting
Research Site
Nashville, Tennessee · Not yet recruiting
Research Site
Nashville, Tennessee · Not yet recruiting
Research Site
Dallas, Texas · Not yet recruiting
Research Site
Houston, Texas · Not yet recruiting
Showing 40 of 124 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.